Bactiguard Holding AB (publ) - Asset Resilience Ratio
Bactiguard Holding AB (publ) (BACTI-B) has an Asset Resilience Ratio of 8.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Bactiguard Holding AB (publ) PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Bactiguard Holding AB (publ)'s Asset Resilience Ratio has changed over time. See Bactiguard Holding AB (publ) balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bactiguard Holding AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Bactiguard Holding AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr44.26 Million | 8.12% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr44.26 Million | 8.12% |
Asset Resilience Insights
- Limited Liquidity: Bactiguard Holding AB (publ) maintains only 8.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bactiguard Holding AB (publ) Industry Peers by Asset Resilience Ratio
Compare Bactiguard Holding AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Bactiguard Holding AB (publ) (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Bactiguard Holding AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.12% | Skr44.26 Million ≈ $4.76 Million |
Skr545.06 Million ≈ $58.66 Million |
-9.68pp |
| 2024-12-31 | 17.80% | Skr116.73 Million ≈ $12.56 Million |
Skr655.91 Million ≈ $70.59 Million |
-0.81pp |
| 2023-12-31 | 18.61% | Skr123.22 Million ≈ $13.26 Million |
Skr662.17 Million ≈ $71.26 Million |
-5.87pp |
| 2022-12-31 | 24.48% | Skr197.73 Million ≈ $21.28 Million |
Skr807.70 Million ≈ $86.92 Million |
-1.14pp |
| 2021-12-31 | 25.62% | Skr217.59 Million ≈ $23.42 Million |
Skr849.29 Million ≈ $91.40 Million |
+24.16pp |
| 2020-12-31 | 1.46% | Skr9.89 Million ≈ $1.06 Million |
Skr675.22 Million ≈ $72.66 Million |
-2.10pp |
| 2019-12-31 | 3.57% | Skr22.88 Million ≈ $2.46 Million |
Skr641.37 Million ≈ $69.02 Million |
+3.24pp |
| 2018-12-31 | 0.32% | Skr1.89 Million ≈ $203.72K |
Skr587.48 Million ≈ $63.22 Million |
-1.52pp |
| 2017-12-31 | 1.85% | Skr11.55 Million ≈ $1.24 Million |
Skr625.39 Million ≈ $67.30 Million |
+1.93pp |
| 2016-12-31 | -0.08% | Skr-525.00K ≈ $-56.50K |
Skr632.07 Million ≈ $68.02 Million |
+0.81pp |
| 2015-12-31 | -0.89% | Skr-6.01 Million ≈ $-646.99K |
Skr676.25 Million ≈ $72.77 Million |
-- |
About Bactiguard Holding AB (publ)
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management … Read more